COMP <GO>
RXRX vs BEAM // NET PROFIT MARGIN
Recursion Pharmaceuticals Inc. (NASDAQ) VS. Beam Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RXRX 1
— BEAM 7
▲ NET PROFIT MARGIN LEADER: BEAM
LAST: $4.24 (-2.53%) • MKT CAP: $2.53B
net-margins
-60.00%
LAST: $28.84 (+0.21%) • MKT CAP: $2.98B
net-margins
-57.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXRX VS. BEAM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXRX | BEAM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -32.10% | -2.90 | BEAM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.95% | -12.09% | -2.86 | BEAM | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | -57.20% | -2.80 | BEAM | /net-margins <GO> |
| Revenue Growth (YoY) | 26.90% | 120.00% | -93.10 | BEAM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.59 | 6.00 | -4.41 | BEAM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | RXRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.1 | 57.7 | -1.59 | BEAM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.53B | $2.98B | -$448.0M | BEAM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXRX REV | BEAM REV | RXRX GROSS % | BEAM GROSS % | RXRX FCF | BEAM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $74.7M | $139.7M | 5.0% | — | -$378.3M | -$360.0M |
| FY 2024 | $58.8M | $63.5M | 23.1% | — | -$372.9M | -$356.2M |
| FY 2023 | $44.6M | $377.7M | — | — | -$289.8M | -$149.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXRX // BETA 1.00
BEAM // BETA —